Dergiler / Turkish Journal of Gastroenterology / 2019 / Cilt: 30 - Sayı: 6

Model for end-stage liver disease and pneumonia: An improved scoring model for critically ill cirrhotic patients with pneumonia

Sayfa
532–540
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

A similar result was obtained in validation cohort.Conclusion: MELD-P, as the first model specifically designed to evaluate the risk of mortality in critically ill patients with cirrhosis andpneumonia, performs well on the mortality assessment of short-term mortality.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Background/Aims: Critically ill patients with cirrhosis with pneumonia are at an increased risk for mortality.
📊
Temel Bulgular & Veri:Only a few accurate predictive models are existing specific to these patients.
💡
Sonuç & Katkı:A similar result was obtained in validation cohort.Conclusion: MELD-P, as the first model specifically designed to evaluate the risk of mortality in critically ill patients with cirrhosis andpneumonia, performs well on the mortality assessment of short-term mortality.
🔬Tür:Modelleme & Sayısal Simülasyon
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

Background/Aims: Critically ill patients with cirrhosis with pneumonia are at an increased risk for mortality. Only a few accurate predictive models are existing specific to these patients. The aim of the present study was to compare the existing prognostic models and todevelop an improved mortality risk model for patients with cirrhosis and pneumonia.Materials and Methods: A total of 231 patients were enrolled in our study (70% training and 30% validation cohorts). All participantswere followed up for at least 21 days. Model for End-stage Liver Disease and Pneumonia (MELD-P) was derived by the Cox proportionalhazards model. The performances of prognostic scoring systems were compared by calculation of the area under the receiver operatingcharacteristic (AUROC) curve.Results: MELD-P showed better discriminative capabilities than existing scoring systems. Four clinical variables, including loge bilirubin(hazard ratio (HR) 1.29, 95% confidence interval (CI) 1.01-1.73), loge international normalized ratio (HR 3.57, 95% CI 1.30-9.78), logepulse oxygen saturation/fraction of inspired oxygen (HR 0.38, 95% CI 0.14-0.99), and vasopressors used (HR 3.72, 95% CI 1.85-7.49),were considered as independent prognostic values associated with 21-day mortality. MELD-P had AUROC curve values of 0.78 (95% CI0.71-0.84) in predicting in-hospital mortality, 0.78 (95% CI 0.70-0.84) at 21-day, 0.88 (95% CI 0.82-0.93) at 14-day, and 0.87 (95% CI0.81-0.92) at 7-day. A similar result was obtained in validation cohort.Conclusion: MELD-P, as the first model specifically designed to evaluate the risk of mortality in critically ill patients with cirrhosis andpneumonia, performs well on the mortality assessment of short-term mortality.

🔖

Bu Makaleye Atıf Yap

GAO, F., CAI, M. X., LIN, M. T., ZHANG, L. Z., RUAN, Q. Z., HUANG, Z. M. (2019). Model for end-stage liver disease and pneumonia: An improved scoring model for critically ill cirrhotic patients with pneumonia. Turkish Journal of Gastroenterology, Cilt: 30 - Sayı: 6, 532–540. https://ajindex.com/articles/408819

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (14)

  1. Tsochatzis EA, Bosch J, Burroughs AK. Liver cirrhosis. Lancet 2014
  2. [CrossRef] 2. Bajaj JS, O’Leary JG, Wong F, Reddy KR, Kamath PS. Bacterial infections in end-stage liver disease: current challenges and future directions. Gut 2012
  3. [CrossRef] 3. Fernandez J, Navasa M, Gomez J, et al. Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatology 2002
  4. [CrossRef] 4. Albillos A, Lario M, Alvarez-Mon M. Cirrhosis-associated immune dysfunction: distinctive features and clinical relevance. J Hepatol 2014
  5. [CrossRef] 5. Wiest R, Lawson M, Geuking M. Pathological bacterial translocation in liver cirrhosis. J Hepatol 2014
  6. [CrossRef] 6. Fagiuoli S, Colli A, Bruno R, et al. Management of infections in cirrhotic patients: report of a consensus conference. Dig Liver Dis 2014
  7. [CrossRef] 7. Cuomo G, Brancaccio G, Stornaiuolo G, et al. Bacterial pneumonia in patients with liver cirrhosis, with or without HIV co-infection: a possible definition of antibiotic prophylaxis associated pneumonia (APAP). Infect Dis 2018
  8. [CrossRef] 8. Jalan R, Fernandez J, Wiest R, et al. Bacterial infections in cirrhosis: A position statement based on the EASL Special Conference 2013. J Hepatol 2014
  9. [CrossRef] 9. Fagiuoli S, Colli A, Bruno R, et al. Management of infections preand post-liver transplantation: report of an AISF consensus conference. J Hepatol 2014
  10. [CrossRef] 10. Viasus D, Garcia-Vidal C, Castellote J, et al. Community-acquired pneumonia in patients with liver cirrhosis: clinical features, outcomes, and usefulness of severity scores. Medicine 2011
  11. [CrossRef] 11. Christou L, Pappas G, Falagas ME. Bacterial infection-related morbidity and mortality in cirrhosis. Am J Gastroenterol 2007
  12. [CrossRef] 12. Srinivasan M, Shetty N, Gadekari S, Thunga G, Rao K, Kunhikatta V. Comparison of the Nosocomial Pneumonia Mortality Prediction (NPMP) model with standard mortality prediction tools. The Journal of hospital infection 2017
  13. [CrossRef] 13. Morris A. ACP Journal Club. Review: CURB65, CRB65, and Pneumonia Severity Index similarly predict mortality in community-acquired pneumonia. Ann Intern Med 2011
  14. Jc4-13. [CrossRef] 14. Barlow G, Nathwani D, Davey P. The CURB65 pneumonia severity score outperforms generic sepsis and early warning scores in predicting mortality in co